An Additional Bladder Biopsy before Surgery in Diagnosing Patients with Non-muscle Invasive Bladder Cancer

Inclusion Criteria

• Clinical evidence of urothelial carcinoma of the bladder.
• Clinically (endoscopic, by physical examination, and/or axial-imaging) deemed non-muscle-invasive tumor of the bladder (cTis-Ta-T1), of any grade, single or multiple, at initial occurrence or recurrent with > 12 months interval free of disease.
• Surgically eligible for the transurethral resection (TUR).
• Patient or authorized proxy needs to have signed the informed consent form.

Exclusion Criteria

• History of any muscle-invasive or non-organ confined bladder tumors (T2 or higher).
• Patients with sessile appearing bladder tumors, which may be T2 or higher stage.
• Diagnosis of urothelial carcinoma involving the prostatic urethra or upper urinary tract.
• Concurrent use of anticoagulation medication or chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin (other than cardio protective doses of 80 mg daily) that has not been appropriately interrupted before the office cystoscopic evaluation.
• Patient deemed medically or psychologically unfit for the surgical procedure.
• Subject has received any investigational medication within 30 days prior to the registration or is scheduled to receive an investigational drug during the course of the study.
• Pregnant or lactating women.